|
论阿托伐他汀对维持性血液透析患者炎症因子的影响 |
| |
【摘要】 目的：探讨不同剂量阿托伐他汀对维持性血液透析(maintenance hemodiabysis MHD)患者炎症因子的影响。方法：选择维持性血液透析的尿毒症患者65例,随机分为10mg组与20mg组，在常规治疗基础上，每晚分别口服阿托伐他汀10mg和20mg，在治疗前、治疗1个月、治疗3个月时观察血清炎症指标:可溶性细胞间黏附分子1(sICAM1)、白介素6(IL6)、血清高敏反应C蛋白(hsCRP)浓度及血压、血脂、血压、营养指标。结果：两组患者治疗1、3个月后血清IL6、hsCRP、sICAM1水平较治疗前明显降低(P<0.05),其中20mg组较10mg组降低更明显(P<0.01);两组治疗1个月时，收缩压及舒张压均有降低但无统计学意义(P>0.05)，3个月后血压较治疗前明显降低(P<0.05),但两组比较无统计学意义。两组治疗1、3个月后 TC、TG、LDLC均较治疗前明显降低(P<0.05),3个月后20mg组TC、LDLC较10mg组明显降低(P<0.05);两组治疗3个月后白蛋白浓度均较治疗前明显增高(P<0.05)。结论：常规服用阿托伐他汀可改善维持性血液透析患者的微炎症状态及脂代谢紊乱。
【关键词】 尿毒症 血液透析 阿托伐他汀 炎症因子
Effect of Different Doses of Atorvastatin on Cytokines and Blood Pressure During Maintenance Hemodialysis in Patients with Chronic Renal Failure LI Yumei,et al.Wenzhou Medical College,Wenzhou(325000),China
Abstract Objective:To investigate the effects of different doses of atorvastatin on serum levels of interlerkin6(IL6),hypersensitive C reactive protein (hsCRP) and soluble intercellular adhesion molecule 1(sICAM1) and blood pressure on chronic renal failure during maintenance hemodialysis(MHD).Methods:Sixtyfive patients with chronic renal failure during MHD were randomly divided into 10 mg atorvastatin group (n=35) and 20 mg atovastatin group (n=30).Both were administered once daily for 12 weeks in addition to a routine therapy.Serum levels of IL6,hsCRP,sICAM1,TG,TC,LDLC,HB,BUN,CRE and blood pressure were [1] [2] [3] [4] [5] 下一页
上一个医学论文： 浅议黄体剥除预防持续性异位妊娠的临床问题
下一个医学论文： 浅论孟鲁司特合博利康尼防治儿童咳嗽变异性哮喘
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 中医论文 >> 正文